CYDY Stock Price, Chart, Stats & News

CytoDyn Inc.
Save
CytoDyn Inc. (CYDY) does not currently pay a dividend.
273.95M
Market cap
–
Current P/E
10.81x
Forward P/E
CYDY chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19).
Similar securities
Based on sector and market capitalization
Report issue





